Evidence map›Paper›PMID 34750146›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2022

A Randomized Double-blind Placebo-controlled Trial of Oral Aspirin for Protection of Melanocytic Nevi Against UV-induced DNA Damage.

Nwanneka Okwundu, Hafeez Rahman, Tong Liu, Scott R Florell, Kenneth M Boucher, Douglas Grossman

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. The Challenge of Melanoma Chemoprevention.Cancer prevention research (Philadelphia, Pa.) · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Nwanneka Okwundu *From the Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah.
Hafeez Rahman *From the Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah.
Tong LiuFrom the Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah.
Scott R FlorellDepartments of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah.
Kenneth M BoucherFrom the Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah.ORCID 0000-0003-2833-0127
Douglas GrossmanFrom the Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah. doug.grossman@hci.utah.edu.ORCID 0000-0003-1790-7023
Huntsman Cancer Institute · USUniversity of Utah · US

Funding

Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
Personalized melanoma chemopreventionR01CA166710 · NCI · UNIVERSITY OF UTAH · PI CASSIDY, PAMELA B., GROSSMAN, DOUGLAS · 2012 to 2016
$1.6M
NCATS NIH HHS UL1 TR002538NCI NIH HHS R01 CA166710
6 · The paper itself

Abstract

DNA damage plays a role in ultraviolet (UV)-induced melanoma. We previously showed that aspirin (ASA) can suppress prostaglandin-E

Indexed as

Nevus, PigmentedSkin NeoplasmsAspirinDNA DamageHumansProspective StudiesUltraviolet RaysAspirin

Identifiers

PMID34750146
PMCPMC8828675
OpenAlexW3213344578

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.